Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Biochem/physiol Actions
Lifitegrast, a potent LFA-1 antagonist (IC50 ~2.98 nM), treats Dry Eye Disease by inhibiting T-cell mediated inflammation. It competitively and rapidly binds LFA-1 on T-lymphocytes, blocking interaction with ICAM-1, which inhibits crucial inflammatory processes like T-cell adhesion, migration, activation, and pro-inflammatory cytokine release (e.g., IFN-γ, TNF-α). This action downregulates T-cell activation signaling and inflammatory gene expression, producing targeted anti-inflammatory effects. Administered topically, Lifitegrast exhibits high ocular retention and bioavailability, ensuring localized biological action with minimal systemic exposure.
Disclaimer
Hygroscopic Store with desiccant
Storage Class
11 - Combustible Solids
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.